CO2023004926A2 - Compuestos de triazolopiridinilo como inhibidores de quinasas - Google Patents
Compuestos de triazolopiridinilo como inhibidores de quinasasInfo
- Publication number
- CO2023004926A2 CO2023004926A2 CONC2023/0004926A CO2023004926A CO2023004926A2 CO 2023004926 A2 CO2023004926 A2 CO 2023004926A2 CO 2023004926 A CO2023004926 A CO 2023004926A CO 2023004926 A2 CO2023004926 A2 CO 2023004926A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- triazolopyridinyl
- kinase inhibitors
- diastereomers
- stereoisomers
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos que tienen la Fórmula (I) y enantiómeros y diastereómeros, estereoisómeros, sales farmacéuticamente aceptables de los mismos, (I) son útiles como moduladores de quinasas, incluida la modulación RIPK1. Todas las variables son como se definen en el presente documento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063093463P | 2020-10-19 | 2020-10-19 | |
| PCT/US2021/055340 WO2022086828A1 (en) | 2020-10-19 | 2021-10-18 | Triazolopyridinyl compounds as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023004926A2 true CO2023004926A2 (es) | 2023-05-08 |
Family
ID=78536657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0004926A CO2023004926A2 (es) | 2020-10-19 | 2023-04-19 | Compuestos de triazolopiridinilo como inhibidores de quinasas |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11767322B2 (es) |
| EP (2) | EP4229056B1 (es) |
| JP (1) | JP2023546166A (es) |
| KR (1) | KR20230092960A (es) |
| CN (1) | CN116802181A (es) |
| AR (1) | AR123793A1 (es) |
| AU (1) | AU2021364302A1 (es) |
| CA (1) | CA3196059A1 (es) |
| CL (1) | CL2023001123A1 (es) |
| CO (1) | CO2023004926A2 (es) |
| IL (1) | IL302113A (es) |
| MX (1) | MX2023004492A (es) |
| PE (1) | PE20240219A1 (es) |
| TW (1) | TW202233614A (es) |
| WO (1) | WO2022086828A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102549952B1 (ko) * | 2017-02-13 | 2023-06-29 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서의 아미노트리아졸로피리딘 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077948A1 (ja) | 2004-02-16 | 2005-08-25 | Daiichi Pharmaceutical Co., Ltd. | 抗真菌作用複素環化合物 |
| EP1765825A1 (en) | 2004-06-25 | 2007-03-28 | Amgen Inc. | Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| EP2444403A1 (en) | 2008-04-18 | 2012-04-25 | Shionogi Co., Ltd. | Heterocyclic compound having inhibitory activity on PI3K |
| WO2010007100A1 (en) | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| WO2010007099A1 (en) | 2008-07-15 | 2010-01-21 | Cellzome Limited | 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| WO2010057877A1 (en) | 2008-11-18 | 2010-05-27 | Cellzome Limited | 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors |
| EP2393813B1 (en) | 2009-02-04 | 2013-07-31 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol |
| WO2014047024A1 (en) | 2012-09-18 | 2014-03-27 | Bristol-Myers Squibb Company | Iap antagonists |
| CA2914668A1 (en) | 2013-06-10 | 2014-12-18 | Volker Schulze | Novel compounds for the treatment of cancer |
| CA2958645A1 (en) | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| US10214537B2 (en) | 2014-10-22 | 2019-02-26 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds |
| EP3209665B1 (en) | 2014-10-22 | 2019-08-14 | Bristol-Myers Squibb Company | Substituted pyrrolotriazine amine compounds as pi3k inhibitors |
| WO2017077968A1 (ja) | 2015-11-05 | 2017-05-11 | 住友化学株式会社 | 縮合複素環化合物 |
| WO2018017435A1 (en) | 2016-07-22 | 2018-01-25 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof |
| EP3575298B1 (en) | 2017-01-24 | 2022-03-02 | Sumitomo Chemical Company, Limited | Fused heterocyclic compound and composition containing same |
| KR102549952B1 (ko) | 2017-02-13 | 2023-06-29 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서의 아미노트리아졸로피리딘 |
| WO2018237370A1 (en) | 2017-06-23 | 2018-12-27 | Accro Bioscience Inc. | HETEROARYL COMPOUNDS AS INHIBITORS OF THE NECROSIS, COMPOSITION AND METHOD OF USE THEREOF |
| PT3704118T (pt) | 2017-10-30 | 2022-02-14 | Bristol Myers Squibb Co | Inibidores de aminoimidazopiridazinas como inibidores de quinase |
| WO2019147782A1 (en) | 2018-01-26 | 2019-08-01 | Bristol-Myers Squibb Company | Aminopyrrolotriazines as kinase inhibitors |
| EA202190759A1 (ru) | 2018-09-13 | 2021-06-17 | Бристол-Маерс Сквибб Компани | Индазолкарбоксамиды в качестве ингибиторов киназ |
| MX2021002509A (es) | 2018-09-13 | 2021-04-28 | Bristol Myers Squibb Co | 1h-indazol carboxamidas como inhibidores de proteina cinasa de interaccion con receptor 1 (ripk1). |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| AU2020246313B2 (en) | 2019-03-22 | 2022-08-04 | Genfleet Therapeutics (Shanghai) Inc. | Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof |
| CN115087651A (zh) | 2019-10-03 | 2022-09-20 | 百时美施贵宝公司 | 作为激酶抑制剂的吲唑甲酰胺 |
| CN114230565B (zh) | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
-
2021
- 2021-10-14 AR ARP210102843A patent/AR123793A1/es unknown
- 2021-10-18 EP EP21805787.5A patent/EP4229056B1/en active Active
- 2021-10-18 PE PE2023001446A patent/PE20240219A1/es unknown
- 2021-10-18 EP EP24159615.4A patent/EP4364737A2/en active Pending
- 2021-10-18 US US17/503,516 patent/US11767322B2/en active Active
- 2021-10-18 TW TW110138596A patent/TW202233614A/zh unknown
- 2021-10-18 JP JP2023523570A patent/JP2023546166A/ja active Pending
- 2021-10-18 CA CA3196059A patent/CA3196059A1/en active Pending
- 2021-10-18 WO PCT/US2021/055340 patent/WO2022086828A1/en active Application Filing
- 2021-10-18 IL IL302113A patent/IL302113A/en unknown
- 2021-10-18 AU AU2021364302A patent/AU2021364302A1/en active Pending
- 2021-10-18 KR KR1020237016535A patent/KR20230092960A/ko unknown
- 2021-10-18 MX MX2023004492A patent/MX2023004492A/es unknown
- 2021-10-18 CN CN202180070933.6A patent/CN116802181A/zh active Pending
-
2023
- 2023-04-18 CL CL2023001123A patent/CL2023001123A1/es unknown
- 2023-04-19 CO CONC2023/0004926A patent/CO2023004926A2/es unknown
- 2023-07-06 US US18/347,703 patent/US20240109888A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR123793A1 (es) | 2023-01-11 |
| EP4229056A1 (en) | 2023-08-23 |
| JP2023546166A (ja) | 2023-11-01 |
| MX2023004492A (es) | 2023-05-10 |
| US11767322B2 (en) | 2023-09-26 |
| AU2021364302A1 (en) | 2023-06-22 |
| PE20240219A1 (es) | 2024-02-16 |
| WO2022086828A1 (en) | 2022-04-28 |
| CN116802181A (zh) | 2023-09-22 |
| AU2021364302A9 (en) | 2024-05-02 |
| CA3196059A1 (en) | 2022-04-28 |
| TW202233614A (zh) | 2022-09-01 |
| EP4229056B1 (en) | 2024-04-10 |
| IL302113A (en) | 2023-06-01 |
| CL2023001123A1 (es) | 2023-09-22 |
| US20240109888A1 (en) | 2024-04-04 |
| KR20230092960A (ko) | 2023-06-26 |
| US20220119388A1 (en) | 2022-04-21 |
| EP4364737A2 (en) | 2024-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201991915A1 (ru) | Аминотриазолопиридины в качестве ингибиторов киназ | |
| UY35630A (es) | Carboxamidas primarias como inhibidores de btk | |
| DOP2016000017A (es) | Nuevos compuestos tricíclicos | |
| EA201100992A1 (ru) | Карбазолкарбоксамидные соединения, применимые в качестве ингибиторов киназы | |
| CO2021017504A2 (es) | Derivados de benzisoxazol sulfonamida | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| NI202000080A (es) | Inhibidores de magl | |
| CL2021001228A1 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| CU24091B1 (es) | Derivados de 2-(piridin-4-il)piridina o sales de los mismos como moduladores de proteína quinasa cdk9 y composiciones farmacéuticas que los comprenden | |
| CY1124984T1 (el) | Αμινοïμιδαζοπυριδινες ως αναστολεις κινασων | |
| CO2023004926A2 (es) | Compuestos de triazolopiridinilo como inhibidores de quinasas | |
| CL2022002341A1 (es) | Compuestos y métodos para modular el empalme | |
| EA202190759A1 (ru) | Индазолкарбоксамиды в качестве ингибиторов киназ | |
| CL2017002745A1 (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| UY36628A (es) | Indazolonas como moduladores de la señalización de tnf | |
| EA202190718A1 (ru) | Индазолкарбоксамиды в качестве ингибиторов киназ | |
| UY39150A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| ECSP16083017A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| CO2023015732A2 (es) | Moduladores de trex1 | |
| CO2023012702A2 (es) | Derivados de diazepina útiles en el tratamiento de clostridium difficile | |
| BR112022005938A2 (pt) | Carboxamidas indazol como inibidores de quinase | |
| CO2023016367A2 (es) | Moduladores de trex1 | |
| EA202091055A1 (ru) | Аминоимидазопиридазины в качестве ингибиторов киназ | |
| UY39695A (es) | Compuestos de azetidinil-piridinilcarbonilo, pirrolidinil-piridinilcarbonilo, piperidinil-piridinilc | |
| CO2023003078A2 (es) | Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de células falciforme |